TP53 and neoplasm: HPV-negative tumors were then screened for TP53, PIKCA, NOTCH1, and CDKN2a mutations; if none of those regions of interest were mutated, then a low-pass sequencing approach was used to identify any somatic tumor mutations or rearrangements [24].